Full Text of SB0509 95th General Assembly
SB0509ham005 95TH GENERAL ASSEMBLY
|
Rep. Jack D. Franks
Filed: 5/30/2007
|
|
09500SB0509ham005 |
|
LRB095 10560 RAS 37416 a |
|
| 1 |
| AMENDMENT TO SENATE BILL 509
| 2 |
| AMENDMENT NO. ______. Amend Senate Bill 509, AS AMENDED, | 3 |
| with reference to page and line numbers of House Amendment No. | 4 |
| 2, as follows: | 5 |
| on page 2, line 15, by deleting " either of "; and | 6 |
| on page 3, line 23, after " distributor ", by inserting " or by an | 7 |
| authorized distributor of record that purchased the product | 8 |
| directly from the manufacturer or one of these entities "; and | 9 |
| on page 4, line 6, after " distributor ", by inserting " or from | 10 |
| an authorized distributor of record that purchased the product | 11 |
| directly from the manufacturer or one of these entities "; and | 12 |
| on page 5, line 19, after " drug ", by inserting " to a patient "; | 13 |
| and |
|
|
|
09500SB0509ham005 |
- 2 - |
LRB095 10560 RAS 37416 a |
|
| 1 |
| on page 5, line 23, by deleting " or "; and | 2 |
| on page 6, line 1, by replacing " patient. " with " patient; or "; | 3 |
| and | 4 |
| on page 6, immediately below line 1, by inserting the | 5 |
| following: | 6 |
| " (6) an authorized distributor to a pharmacy or other | 7 |
| persons licensed to dispense or administer the drug. "; and | 8 |
| on page 9, line 12, after " pharmacy ", by inserting " , mail | 9 |
| order pharmacy, "; and | 10 |
| on page 9, lines 14 and 15, by replacing " manufacturer or to " | 11 |
| with " manufacturer, the originating wholesale distributor, | 12 |
| or "; and | 13 |
| on page 12, line 9, after " affiliates ", by inserting | 14 |
| " licensed "; and | 15 |
| on page 23, by replacing lines 9 through 12 with the following: | 16 |
| "stock, to any crime under the laws of the United States or | 17 |
| any state or territory of the United States that is a | 18 |
| felony or a misdemeanor, of which an essential element is | 19 |
| dishonesty, or any crime that is directly related "; and |
|
|
|
09500SB0509ham005 |
- 3 - |
LRB095 10560 RAS 37416 a |
|
| 1 |
| on page 25, lines 17 and 18, by replacing " processor, and such | 2 |
| returns or exchanges, " with " processor. Returns or exchanges of | 3 |
| prescription drugs, saleable or otherwise, "; and | 4 |
| by replacing line 22 on page 27 through line 20 on page 28 with | 5 |
| the following: | 6 |
| " (a) Each person who is engaged in the wholesale | 7 |
| distribution of prescription drugs, including repackagers, but | 8 |
| excluding the original manufacturer of the finished form of the | 9 |
| prescription drug, that leave or have ever left the normal | 10 |
| distribution channel shall, before each wholesale distribution | 11 |
| of the drug, provide a pedigree to the person who receives the
| 12 |
| drug. A retail pharmacy, mail order pharmacy, or chain pharmacy | 13 |
| warehouse must comply with the requirements of this Section | 14 |
| only if the pharmacy or chain pharmacy warehouse engages in the | 15 |
| wholesale distribution of prescription drugs. On or before July | 16 |
| 1, 2009, the Department shall determine a targeted | 17 |
| implementation date for electronic track and trace pedigree | 18 |
| technology. This targeted implementation date shall not be | 19 |
| sooner than July 1, 2010. Beginning on the date established by | 20 |
| the Department, pedigrees may be implemented through an | 21 |
| approved and readily available system that electronically | 22 |
| tracks and traces the wholesale distribution of each | 23 |
| prescription drug starting with the sale by the manufacturer | 24 |
| through acquisition and sale by any wholesale distributor and | 25 |
| until final sale to a pharmacy or other authorized person |
|
|
|
09500SB0509ham005 |
- 4 - |
LRB095 10560 RAS 37416 a |
|
| 1 |
| administering or dispensing the prescription drug. This | 2 |
| electronic tracking system shall be deemed to be readily | 3 |
| available only upon there being available a standardized system | 4 |
| originating with the manufacturers and capable of being used on | 5 |
| a wide scale across the entire pharmaceutical chain, including | 6 |
| manufacturers, wholesale distributors, and pharmacies. | 7 |
| Consideration must also be given to the large-scale | 8 |
| implementation of this technology across the supply chain and | 9 |
| the technology must be proven to have no negative impact on the | 10 |
| safety and efficacy of the pharmaceutical product. "; and | 11 |
| on page 31, line 9, by replacing " Section 57 " with " Section | 12 |
| 56 ".
|
|